H3K27me3 does not orchestrate the expression of lineage-specific markers in hesc-derived hepatocytes in vitro by Vanhove, Jolien et al.
Stem Cell Reports
ArticleH3K27me3 Does Not Orchestrate the Expression of Lineage-Specific
Markers in hESC-Derived Hepatocytes In Vitro
Jolien Vanhove,1,5,* Mariaelena Pistoni,1,5,* Marc Welters,1 Kristel Eggermont,1 Veerle Vanslembrouck,1
Nicky Helsen,1 Ruben Boon,1 Mustapha Najimi,2 Etienne Sokal,2 Philippe Collas,3 J. Willem Voncken,4
and Catherine M. Verfaillie1
1Department Development and Regeneration, Stem Cell Institute, KU Leuven, Leuven 3000, Belgium
2Laboratory of Pediatric Hepatology andCell Therapy, Universite´ Catholique de Louvain, Cliniques St-Luc – Institut de Recherche Expe´rimentale et Clinique
(IREC), Brussels 1200, Belgium
3Faculty of Medicine, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo 0372, Norway
4Department of Molecular Genetics, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands
5Co-first author
*Correspondence: jolien.vanhove@med.kuleuven.be (J.V.), mariaelena.pistoni@gmail.com (M.P.)
http://dx.doi.org/10.1016/j.stemcr.2016.06.013SUMMARYAlthough pluripotent stem cells can be differentiated into the hepatocyte lineages, such cells retain an immature phenotype. As the
chromatin state of regulatory regions controls spatiotemporal gene expression during development, we evaluated changes in epigenetic
histonemarks in lineage-specific genes throughout in vitro hepatocyte differentiation fromhuman embryonic stem cells (hESCs). Active
acetylation andmethylationmarks at promoters and enhancers correlatedwith progressive changes in gene expression. However, repres-
sion-associated H3K27me3 marks at these control regions showed an inverse correlation with gene repression during transition from
hepatic endoderm to a hepatocyte-like state. Inhibitor of Enhancer of Zeste Homolog 2 (EZH2) reduced H3K27me3 decoration but did
not improve hepatocyte maturation. Thus, H3K27me3 at regulatory regions does not regulate transcription and appears dispensable
for hepatocyte lineage differentiation of hESCs in vitro.INTRODUCTION
Human embryonic stem cells (hESCs) and induced plurip-
otent stem cells (hiPSCs) are a renewable cell source for the
generation of human hepatocytes that could be used for
drug toxicity and metabolization studies (Baxter et al.,
2010; Mann, 2015; Ulvestad et al., 2013; Zhang et al.,
2013; Zhu and Huangfu, 2013). Although many groups
(Baxter et al., 2015; Chen et al., 2012; Godoy et al., 2015;
Hannan et al., 2013; Shan et al., 2013; Siller et al., 2015;
Ulvestad et al., 2013), including ours (Helsen et al., 2016;
Roelandt et al., 2012), have generated pluripotent stem
cell (PSC)-derived progeny displaying hepatocyte charac-
teristics, these cells are more akin to fetal than post-natal
hepatocytes, and are therefore often termed hepato-
cyte-like cells (HLCs). For instance, HLCs continued to ex-
press a-fetoprotein (AFP), a typical fetal hepatocyte marker
(Schmelzer et al., 2006).
At the molecular level, cell fate is controlled by epige-
netic mechanisms that modulate chromatin structure
and thereby control utilization of genetic informa-
tion (Boland et al., 2014; Meissner, 2010). Changes in
chromatin structure are, in part, induced by specific
post-translational modifications of nucleosomal and
non-nucleosomal histones (Bannister and Kouzarides,
2011; Harshman et al., 2013). Gene activity has been
linked to high levels of tri- and dimethylation of histone
3 lysine 4 (H3K4me3/me2) together with binding of RNA192 Stem Cell Reports j Vol. 7 j 192–206 j August 9, 2016 j ª 2016 The Auth
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kholok et al., 2005; Schneider et al., 2004; Schubeler
et al., 2004). However, H3K4me3 promoter marking by
itself does not predict transcriptional activity (Guenther
et al., 2007). In hESCs, for instance, promoters of key
developmental control genes are marked with both
H3K4me3 and repression-associated histone 3 lysine 27
trimethylation (H3K27me3), resulting in a low transcrip-
tional activity status (Azuara et al., 2006; Bernstein et al.,
2006; Mikkelsen et al., 2007).
In addition to promoters, enhancers play a critical role in
the regulation of tissue-specific gene expression (Heintz-
man et al., 2009; Ong and Corces, 2012; Wamstad et al.,
2012). Enhancer elements are typically located in relatively
‘‘accessible’’ chromatin, i.e., hypersensitive to DNase diges-
tion, often coincidewith CpG-poor regions, and act in con-
cert with non-coding RNAs to co-regulate gene expression
(Boland et al., 2014; Calo and Wysocka, 2013; Heintzman
et al., 2007; Lam et al., 2014; Rada-Iglesias et al., 2011; Sta-
dler et al., 2011; Xie et al., 2013b). Although enhancers are
typically decorated with mono-methylated H3K4 marking
(H3K4me1), only a fraction of H3K4me1-marked elements
are engaged in transcription in a tissue-specific manner
(Boland et al., 2014; Calo and Wysocka, 2013; Creyghton
et al., 2010; Heintzman et al., 2009; Rada-Iglesias et al.,
2011; Visel et al., 2009). In hESCs, poised enhancers harbor
H3K4me1 and H3K27me3, while active enhancers are co-
marked by H3K4me1 and acetylation of histone 3 lysineor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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27 (H3K27ac) (Calo and Wysocka, 2013; Creyghton et al.,
2010; Pekowska et al., 2011).
We hypothesized that mapping histone modifications
at promoter and enhancer regions of key pluripotency,
hepatic endoderm, and hepatocyte marker genes is likely
to provide invaluable information regarding the relevance
of epigenetic marking at such regulatory regions during
the in vitro hESC-hepatocyte differentiation process that
could be used to improve such differentiation protocols.
Although a growing number of studies has addressed
epigenetic regulation in other cellular contexts, such as
for instance b cells (Xie et al., 2013a), neuronal cells (Mik-
kelsen et al., 2007), or cardiomyocytes (Wamstad et al.,
2012), to our knowledge, thus far only one study has
been published wherein histone modifications at pro-
moters in the context of hepatocyte differentiation were
mapped (Kim et al., 2011).
Here, we examined epigenetic markings in undifferen-
tiated hESCs, hepatocyte nuclear factor a (HNF4A+)-en-
riched hepatic endoderm cells (HECs), and a1-antitrypsin
(AAT+)-enriched HLCs. We also compared the epigenetic
status of AAT+ HLCs with uncultured primary human
hepatocytes (PHHs). Our studies provide important
insights into epigenetic changes that accompany hepato-
cyte lineage commitment in vitro, and are expected to
contribute to the advancement of in vitro generation of
mature functional hepatocytes from stem cells.RESULTS
Alterations in Histone Profile Correlate with Dynamic
Changes in Gene Transcription
To address dynamic changes of histone modifications
during hepatocyte commitment of hESCs in vitro, we
compared histone profiles at promoter and enhancer
regions of a selected number of pluripotency, hepatic endo-
derm, and hepatocyte marker gene specific loci in hESCs,
HECs, and HLCs (Figure 1A). As day-8 HECs (d8-HECs)
and d28-HLCs represent mixed cell populations, we iso-
lated HNF4A+ cells (31.3% ± 9.0% of d8-hESC progeny)
and AAT+ cells (54.1% ± 20.5% of d28-hESC progeny) by
fluorescence-activated cell sorting (FACS) to be able to
study more homogeneous hepatocyte precursor popula-Figure 1. hESC-Derived Hepatic Lineage: Two Stages of Lineage S
(A) Schematic overview of the hepatocyte differentiation protocol.
(B and C) Representative FACS sorting plots for HNF4A on day 8 (B) and
(left panels).
(D and E) Relative expression (to GAPDH) of OCT4, HNF4A, AFP, ALB, A
(D) and d28-AAT+ (black)/AAT (white) cells (E).
(F and G) Enrichment of H3K4me3/me2/me1, H3K27ac, and H3K27m
panels) of selected genes in d8-HNF4A+ (black)/HNF4A(white) (F) a
Data represent mean ± SEM of nR 3 independent experiments. See
194 Stem Cell Reports j Vol. 7 j 192–206 j August 9, 2016tions (Figures 1B, 1C, S1A, and S1B). qRT-PCR confirmed
the enrichment for transcripts of the selected lineage-spe-
cific marker genes in the d8-HNF4A+ or d28-AAT+ cell pop-
ulations compared with the d8-HNF4A or d28-AAT cells,
respectively (Figures 1D and 1E). To correlate gene expres-
sion with a specific histone profile, we analyzed the enrich-
ment of known active (H3K4me3, H3K4me2, H3K4me1
and H3K27ac) and repressive (H3K27me3) histone marks
at promoters and enhancers of the same lineage-specific
marker genes by chromatin immunoprecipitation (ChIP)-
qPCR in the sorted HNF4A+/HNF4A and AAT+/AAT
populations (Figures 1F and 1G). To demonstrate the effec-
tiveness and validity of the ChIP-qPCR approach, we first
analyzed the histone profile at the promoter region of
GAPDH, a housekeeping gene expressed throughout differ-
entiation. As expected, the promoter region was preferen-
tially decorated with H3K4me3/me2 in all cell populations
assessed. In contrast, promoters of MYOD1 and HOXD11,
not active in hESCs, HECs, or HLCs, were marked with
H3K27me3 (Figures S1C and S1D).
To investigate the relationship between the expres-
sion of the different genes and subsequently also histone
enrichment, we performed mediation analysis on the
d8-HNF4A+/ cells (Krull and MacKinnon, 1999). This
demonstrated that gene expression, averaged over all
genes, was 2.8-fold higher (95% confidence interval [CI]
78-fold decrease to 35-fold increase) in the HNF4A+
compared with HNF4A cells (Figure S1E), confirming the
enrichment by FACS sorting. In line with our expectations,
the higher transcript levels in the HNF4A+ cells were posi-
tively correlated with higher enrichment for all active
marks (H3K4me3/me2/me1 and H3K27ac) and inversely
correlated with H3K27me3 markings at both regulatory
regions (Figures 1D and S1E). Thus, these data indicate
that changes in transcription correlate with the alterations
observed at the histone profile.H3K27me3 in the Regulatory Regions of Mature
Hepatocyte Genes of d28-AAT+ HLCs May Prevent
Differentiation to Mature Hepatocytes
We next compared the gene expression and histone pro-
files at promoters and enhancers of selected hepaticmarker
genes throughout differentiation (Figures 2A–2E). We alsopecification Can Be Enriched
AAT on day 28 (C) (right panels) and corresponding isotype controls
AT, and CYP3A4 in sorted d8-HNF4A+ (black)/HNF4A (white) cells
e3 histone marks at promoters (left panels) and enhancers (right
nd d28-AAT+ (black)/AAT (white) cells (G).
also Figure S1.
(legend on next page)
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compared the gene expression and histone profile in d28-
AAT+ sorted cells with PHHs, as this potentially provides
important information with which to optimize differentia-
tion protocols (Figures 2A–2E).
As expected, nucleosomes at the GAPDH promoter in
hESCs, d8-HNF4A+, and d28-AAT+ cells and PHHs were
preferentially marked with H3K4me3/2, while MYOD1
and HOXD11 promoters were marked with H3K27me3
(Figures S2A and S2B).
Transcripts of the transcription factor (TF)HNF4A, which
regulates expression of several hepatocyte genes and plays
a critical role in liver development, were most highly
expressed in d8-HNF4A+ cells, at levels similar to those
in PHHs. Levels of H3K27me3 at the HNF4A promoter
and enhancer of d8-HNF4A+ cells and PHHs were similar,
while active marks (especially H3K27ac; enhancer) were
slightly higher in PHHs than in d8-HNF4A+ cells (Fig-
ure 2A). The lower HNF4A transcript levels in d28-AAT+
compared with d8-HNF4A+ cells correlated with increased
H3K27me3 at the HNF4A promoter and enhancer, while
levels of H3K4me3/2/1 and H3K27ac were comparable in
both cell populations (Figure 2A).
Transcripts for AFP, a typical fetal plasma protein, were
highest in d8-HNF4A+ cells and lower d28-AAT+ cells and
PHHs. As observed for HNF4A, a slight increase in active
marks at both the AFP promoter and enhancer was
observed in d8-HNFA+ cells compared with hESCs, whereas
H3K27me3 levels remained relatively low (Figure 2B).
Increased H3K27me3 at AFP promoter/enhancer regions
in d28-AAT+ cells accompanied reduced AFP expression,
while active marks remained unchanged (Figure 2B). Of
note, H3K27me3 levels at the AFP promoter/enhancer
regions in PHHs were even lower than in d28-AAT+ cells,
even though the expression was lower in PHHs compared
with d28-AAT+ cells (Figure 2B).
Transcripts of ALB, an important serum protein
synthesized by the liver, were significantly induced
throughout differentiation (Figure 2C). No changes in
repressive and active marking at the ALB promoter and
enhancer were seen between hESCs and d8-HNF4A+
cells. As expected, active marks (H3K4me3 but not
H3K27ac) at the ALB enhancer and promoter were
higher in d28-AAT+ than in d8-HNF4A+ cells. Unexpect-
edly, higher levels of H3K27me3 were found at the pro-Figure 2. Gene Expression and Histone Modifications in Promoter
Cells, d28-AAT+ Cells, and PHHs
Relative gene expression (to GAPDH) (left panels) and epigenetic p
modifications at the promoter (middle panels) and enhancer (right pan
genes in hESCs (white), d8-HNF4A+ cells (light gray), d28-AAT+ cells
Data represent mean ± SEM of nR 3 independent experiments. *p <
gene expression and histone enrichment for d8-HNF4A+ and d28-AA
Figure 1. See also Figure S2.
196 Stem Cell Reports j Vol. 7 j 192–206 j August 9, 2016moter and enhancer of ALB in 28-AAT+ compared with
d8-HNF4A+ cells (Figure 2C).
Transcripts for AAT, another serum protein synthesized
by the liver, were also significantly induced throughout
differentiation (Figure 2D). In hESCs and d8-HNF4A+ cells,
active and repressive marks at the AAT promoter and
enhancer were low (Figure 2D). Compared with d8-
HNF4A+ cells, in d28-AAT+ cells the AAT promoter was
highly enriched for H3K4me3/2 but not H3K27ac, and
the AAT enhancer also contained more active marks
(H3K27ac and H3K4me3). However, similar to the ALB
regulatory regions, H3K27me3 at the AAT promoter/
enhancer was significantly higher in d28-AAT+ than in
d8-HNF4A+ cells (Figure 2D). Enrichment for active marks
at the promoter and enhancer of AAT d28-AAT+ cells and
PHHs appeared to correlate best with increased expression,
whereby histone methylation was more prominent at the
AAT promoter, and histone acetylation at its enhancer.
Again, H3K27me3 marking did not correlate with tran-
scriptional activity.
In line with the fact that HLCs remain immature, tran-
script levels of CYP3A4, responsible for metabolization of
±50% of drugs, were very low in d28-AAT+ cells compared
with PHHs. In PHHs, an active chromatin status of the
CYP3A4 promoter and enhancer was seen (Figure 2E). In
d28-AAT+ HLCs, active marks in the CYP3A4 promoter
and enhancer were not significantly different from PHHs.
However, levels of H3K27me3 were higher in d28-AAT+
cells compared with PHHs (Figure 2E).
Comparing d28-AAT+ cells and PHHs demonstrated that
transcript levels for all lineage-specific genes were 95 times
lower (95% CI 62–99) in hESC-derived HLCs compared
with PHHs, confirming the immaturity of theHLCs derived
in vitro (Figure S2D) (Baxter et al., 2015; Godoy et al.,
2015). Furthermore, we found that lower expression levels
in d28-AAT+ cells were associated with higher H3K27me3
and lower activemarking at both promoters and enhancers
of all marker genes tested when compared with the PHHs
(Figure S2D). This suggests that inducing a more active
histone profile will be necessary to create more mature
hESC-derived HLCs in vitro.
Thus, we observed a good correlation between transcrip-
tional activity and active marks at the regulatory regions of
hepatic endoderm, and early and more mature hepatocytes and Enhancers of Hepatic Marker Genes in hESCs, d8-HNF4A+
atterns of H3K4me3/me2/me1, H3K27ac, and H3K27me3 histone
els) of hepatic HNF4A (A), AFP (B), ALB (C), AAT (D), and CYP3A4 (E)
(dark gray), and PHHs (black).
0.05, **p < 0.01, ***p < 0.001 by Student’s t test. Note that both
T+ cells represented are identical to the HNF4A+ and AAT+ data in
Figure 3. mRNA Transcript, Protein Levels, and Functional Analysis of hESC-Derived HLCs Treated with or without DMSO
(A) Relative gene expression (to GAPDH, log scale) analysis represented in a heatmap of pluripotent, fetal hepatic, mature hepatic, drug
transporter, and hepatic TF marker genes in cells treated with or without DMSO, FHs, and PHHs.
(B) Representative FACS plots for AAT (right panels) and isotype controls (left panels) on d28-hESC-derived HLCs obtained in the presence
or absence of DMSO.
(legend continued on next page)
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marker genes in hESCs, d8-HNF4A+ cells, d28-AAT+ cells,
and PHHs. However, higher H3K27me3 marks at pro-
moters and enhancers of ALB, AAT, and CYP3A4 in d28-
AAT+ compared with d8-HNF4A+ cells did not correlate
with the higher transcript levels for ALB and AAT in
d28-AAT+ cells. Immunoblotting confirmed the global in-
crease in cellular H3K27me3 in d28-AAT+ compared with
d8-HNF4A+ cells (Figure S2C). Of note, PHHs expressed
significantly higher levels of all hepatic marker genes
compared with d28-AAT+ cells, which correlated with
higher active and lower inhibitorymarks at both regulatory
regions. Thus, the continued presence of H3K27me3 at
regulatory regions of hepatocyte genes during in vitro dif-
ferentiationmay be responsible for suboptimal maturation
of HLCs, suggesting that removal of this mark might be
needed to attain full HLC maturation.
DMSO Improves hESC-DerivedHLCHomogeneity, but
Not HLC Maturation, with Persistent H3K27me3 on
Regulatory Regions of Hepatocyte Marker Genes
As DMSOmay improve differentiation of stem cell-derived
hepatocytes (Basma et al., 2009; Czysz et al., 2015; Duan
et al., 2010; Hay et al., 2008; Kanebratt and Andersson,
2008; Kondo et al., 2014; Szkolnicka et al., 2014; Ulvestad
et al., 2013), we reassessed histone modifications at regu-
latory regions of hESC progeny from cultures containing
DMSO. Addition of 0.6% DMSO throughout the differenti-
ation protocol resulted in increased expression of the
mature hepatocyte genes AAT, CYP3A4, CYP2A6, G6PC,
PEPCK, and APOA1, and the mature hepatocyte TFs
HNF3B, HNF3G, CEBPA, and PROX1 on day 28 (Figure 3A).
Nevertheless, the expression profile of a broad panel of
fetal markers (AFP, CYP3A7, and GSTp) and mature hepa-
tocyte TFs, genes, and drug transporters of d28-HLCs
from DMSO-treated cultures resembled fetal, not mature
hepatocytes (Figure 3A), in line with other publications
(Baxter et al., 2015; Chen et al., 2012; Godoy et al., 2015;
Hannan et al., 2013; Shan et al., 2013; Siller et al., 2015;
Ulvestad et al., 2013).
In d28-HLCs, the yield of AAT+ andHNF4A+ cells is ±70%
and ±50%, respectively, compared with ±50% AAT+ cells
and ±30% HNF4A+ cells in HLCs from cultures without
DMSO (Figures 3B and 3C). Addition of DMSO also signif-
icantly enhanced CYP3A4 activity by 8- to 10-fold (Fig-
ure 3D). To gain insights into the mechanism underlying(C) Representative immunofluorescence images for HNF4A, AFP, ALB, A
without or with DMSO.
(D) Functional CYP3A4 activity in non-treated (black) or DMSO-treate
(E) Relative gene expression (to GAPDH) for OCT4 and hepatic markers
with (white) or without (black) DMSO.
Data, except for (C), represent mean ± SEM of nR 3 independent expe
also Figure S3.
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days 8 and 28, respectively, and the increased expression
of hepatocyte markers in DMSO-treated cultures, we fol-
lowed the expression of OCT4, HNF4A, AFP, ALB, AAT,
and CYP3A4 throughout differentiation in the presence
or absence of DMSO. Improved expression of hepatocyte
transcripts in response to DMSO was only seen on days
20 and 28 (Figure 3E).
We next isolated AAT+ cells from DMSO-treated cul-
tures on day 28, and compared their expression profile
with AAT+ cells from cultures without DMSO. Transcript
levels for nearly all genes tested were not statistically
different (Figure 4C). Thus, DMSO did not appear to
enhance the maturation of HLCs. However, qRT-PCR (Fig-
ure S3B) and FACS/immunocytochemistry (ICC) analysis
(Figures S3C and S3D) on d4-progeny demonstrated that
DMSO significantly increased the fraction of definitive
endoderm cells (CXCR4+/C-kit+ and SOX17+ cells), which
might be responsible for the increased homogeneity of
d28-HLCs.
We compared the gene expression and epigenetic
marks for OCT4, HNF4A, AFP, ALB, AAT, and CYP3A4 in
d8-HNF4A+ and d28-AAT+ enriched populations from
DMSO-treated cultures, with results obtained in the
absence of DMSO (Figures 1 and 2). Differences in tran-
script levels were not detected in d8-HNF4A+ cells from
cultures with or without DMSO (Figure 4A) and not in
H3K27me3 marks at promoters and enhancers of the he-
patic marker genes. A moderate increase in H3K27ac and
H3K4me2/1 (not H3K4me3) marking was observed in
DMSO-treated HNF4A+ cells (Figure 4B). Consistent with
the results obtained for d8-HNF4A+ cells, in DMSO-treated
d28-AAT+ cells neither transcript levels (Figure 4C) nor
H3K27me3 enrichment at promoters and enhancers of
ALB, AAT, and CYP3A4 (Figure 4D) were altered compared
with d28-AAT+ cells from cultures without DMSO. This
further indicates that DMSO does not enhance HLC matu-
ration. Moreover, global H3K27me3 levels were higher in
d28-DMSO-treated cells (Figure S4C). Interestingly, total
H3 levels were lower in d28-AAT+ cells differentiated in
the presence of DMSO (Figures S4A and S4B). In addition,
H3K27ac and H3K4me3/2 appeared to be lower at the reg-
ulatory regions of ALB, AAT, and CYP3A4 of d28-AAT+ cells
derived from cultures withDMSO (Figure 4D). However, we
detected an increased presence of POL2RA at nearly allAT (magnification 203; scale bar, 50 mm) on day 20 for cells treated
d (white) HLCs.
at different time points (days 4, 12, 20, and 28) of differentiation
riments. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. See
(legend on next page)
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gene promoters and enhancers in AAT+ cells derived from
DMSO cultures (Figure 4D).
Thus, addition of DMSO during hepatocyte differen-
tiation improved commitment to definitive endoderm,
which correlated with a more homogeneous population
of d28-AAT+ HLCs. However, none of the transcripts and
epigenetic marks at the promoter and enhancer of imma-
ture and mature hepatocyte marker genes in d8-HNF4A+
HECs and d28-AAT+ HLCs were affected by addition of
DMSO. One exception was the lower levels of active marks
in mature hepatocyte gene regulatory regions of DMSO-
treated d28-AAT+ cells. However, we observed higher
POL2RA levels and lower total H3 levels in nearly all gene
promoters and enhancers. Although we cannot formally
exclude the possibility that some loci, particularly during
early differentiation, are sensitive to global or local alter-
ation of acetylation, this observation may suggest that
DMSO affects differentiation in general by altering chro-
matin accessibility in a more global fashion, as suggested
by Lapeyre and co-workers (Lapeyre and Bekhoe, 1974;
Stratling, 1976).
EZH2 Inhibition Does Not Improve In Vitro
Hepatocyte Differentiation from hESCs
As we consistently found high levels of H3K27me3 at
promoters and enhancers of d28-AAT+ cells compared
with PHHs (Figures 2A–2E), we hypothesized that removal
of H3K27me3 might allow maturation of HLCs to a more
mature PHH phenotype. As EZH2 is the histone methyl-
transferase that catalyzes H3K27 trimethylation (Figure 5A)
(Verma et al., 2012), we supplemented the culture medium
with an inhibitor against EZH2 (GSK-343, hereafter EZH2i)
to reduce H3K27me3 levels, between days 6 and 16 when
levels of H3K27me3 marks at marker gene promoters and
enhancers increased (Figures 5B, 2A–2E, and S2C). An addi-
tional rationale to explore the role of EZH2was provided by
the observation that EZH2 transcripts were higher in d28-
AAT+ HLCs compared with PHHs (Figure S5A).
We reassessed transcripts for mature hepatocyte marker
genes and the histone profiles at both regulatory regions
of these genes in FACS-sorted AAT+ cells on day 28 (Fig-
ure 5B). Addition of EZH2i to the differentiating hESCs re-
sulted in a global reduction of H3K27me3. This effect wasFigure 4. Chromatin Modifications at Promoters and Enhance
without DMSO
(A and C) Relative gene expression (to GAPDH) of pluripotent and hepa
cultures with (white) or without (black) DMSO. Data represent mean
(B and D) Enrichment of H3K4me3/me2/me1, H3K27ac and H3K27m
panels) of OCT4, HNF4A, AFP, ALB, AAT, and CYP3A4 genes in d8-HNF4
AAT+ DMSO, black) or with DMSO (HNF4A+/AAT+ +DMSO, white). Note tha
identical to the HNF4A+ and AAT+ data in Figure 2. Data represent me
See also Figure S4.
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EZH2i and DMSO, a known HDAC inhibitor (Figure 5C).
ChIP-qPCR analysis of EZH2i-treated d28-AAT+ cells re-
vealed a >50% reduction in H3K27me3 at both regulatory
regions of OCT4, HNF4A, AFP, ALB, AAT, and CYP3A4 (Fig-
ure 5D). H3K4me3 enrichment appeared to be increased
overall upon combined EZH2i/DMSO treatment (Fig-
ure S5B). However, the 50% reduction of H3K27me3 did
not result in a significant increase ofmature hepaticmarker
transcripts in the d28-AAT+ cells, regardless of the differen-
tiation protocol (Figure 5E). In line with the qRT-PCR re-
sults, addition of EZH2i (in both differentiation protocols)
did not increase the fraction of AAT+ or HNF4A+ cells (Fig-
ures 5F and 5G) on day 28. Thus, reducing H3K27me3
by 50% at both regulatory regions of mature hepatocyte
marker genes by EZH2 inhibition did not improve the
maturation of AAT+ HLCs.DISCUSSION
hPSC-derived hepatocytes are an attractive, alternative cell
system for PHHs to test the safety, efficacy, andmetaboliza-
tion of new chemical entities. However, to date most hPSC
differentiation protocols yield cells with phenotypic char-
acteristics of fetal rather thanmature hepatocytes.Multiple
studies demonstrated that hPSC-derived hepatocytes show
inferior drug-metabolizing enzyme activity/expression
(e.g., CYP3A4 and CYP2A6), and lower levels of transporter
proteins (e.g.,NTCP orMRP2), and continue to express AFP,
a typical fetal hepatocyte marker (Baxter et al., 2015; Chen
et al., 2012; Godoy et al., 2015; Hannan et al., 2013; Shan
et al., 2013; Siller et al., 2015; Ulvestad et al., 2013).
Consistently, we found that d28-hESC progeny continue
to express AFP, and that transcripts for numerous primary
hepatocyte TFs and functional genes were at significantly
lower levels in d28-hESC progeny than in PHHs. Likewise,
mRNA levels of some TFs and functional genes were also
lower than in hepatocytes from embryos between 20 and
38 weeks.
As epigenetic regulatory mechanisms control DNA-
templated activities, including gene transcription, we hy-
pothesized that evaluating the nature and dynamics ofrs of FACS-Sorted HNF4A+ and AAT+ Cells Treated with or
tic marker genes in d8-HNF4A+ cells (A) and d28-AAT+ cells (C) from
± SEM of n = 3 independent experiments.
e3, and POL2RA at promoters (left panels) and enhancers (right
A+ cells (B) and d28-AAT+ cells (D) treated either without (HNF4A+/
t HNF4A+ DMSO and AAT+ DMSO data represented in these graphs are
an ± SD of nR 2 independent experiments.
(legend on next page)
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epigenetic changes at gene regulatory regions during hepa-
tocyte commitment of hESCs and comparing differences
between HLCs and PHHsmight identify important hurdles
to be overcome to generate more mature hepatocytes
from PSCs. Therefore, we investigated histone marking at
gene promoters and enhancers of a number of key genes
expressed during hepatocyte differentiation. To avoid as-
sessing histone marks in mixed hESC progeny, we isolated
pure fractions of d8-HNF4A+ and d28-AAT+ cells.
In accordance with an earlier report, histone marks asso-
ciated with transcriptional activity at the promoters of the
HNF4A and AFP genes in d8-HNF4A+ cells correlated with
the gene transcriptional status (Kim et al., 2011). We
further demonstrated that this correlation was also true
for the enhancers. In addition, active H3K4me2/me3
and H3K27ac at ALB and AAT gene promoters and en-
hancers clearly coincided with increased expression of
these genes between days 8 and 28. Surprisingly, we
observed that H3K27me3 at promoters and enhancers of
hepatoblast/hepatocyte marker genes were significantly
higher in d28-AAT+ HLCs than in d8-HNF4A+ HECs,
even though transcript levels for these genes increased
significantly by day 28, even if they remained signifi-
cantly lower than in PHHs. These results contradict
earlier published results (Kim et al., 2011). A recent
study on in vivo endocrine progenitor development also
demonstrated gain of H3K27me3 at regulatory regions of
genes involved in differentiation and morphogenesis
(Xu et al., 2014).
Persistent marking of regulatory gene regions by
H3K27me3 despite increased gene transcription supports
the notion that H3K27me3might not be the only determi-
nant of gene activity. A similar finding has been reported
recently in the context of transcriptional activation of the
immediate-early gene ATF3, in response to serum stimula-
tion: ATF3 induction occurred in the presence of the pre-
sumed repressive H3K27me3 and did not require removal
of the mark (Prickaerts et al., 2012).Figure 5. Effect of EZH2 Inhibition on hESC-Derived HLCs Treated
Transcript Levels
(A) Schematic overview of EZH2 function and effect of GSK-343.
(B) Schematic overview of hepatocyte differentiation protocol with the
inhibitor [EZH2i]) was added.
(C) Western blot for H3K27me3 in FACS-sorted AAT+ cells at day 28 obta
the EZH2i. The molecular weight size marker was cropped from the ge
(D) Graphs represent fold change enrichment of H3K27me3 at promote
bars) compared with non-treated cells (line) in both d28-AAT+ sorted
(E) Relative gene expression (to GAPDH) profile of OCT4 and hepatic
without (black) EZH2i.
(F and G) Percent AAT+ cells (by FACS) (F) and percent HNF4A+ cells (b
(line) in d28 progeny with or without DMSO.
Data, except for (C), represent mean ± SEM of n = 3 independent exp
202 Stem Cell Reports j Vol. 7 j 192–206 j August 9, 2016We also compared histone modifications in d28-AAT+
HLCs with those in uncultured PHHs to determine whether
specific epigenetic marks might be responsible for the
incomplete maturation of HLCs. This revealed that active
marks in hepatocytemarker gene promoters and enhancers
were similar in d28-AAT+HLCs andPHHs,whileH3K27me3
marks were significantly higher in d28-AAT+ cells compared
with PHHs. This suggested that H3K27me3marking in part
explains the apparent inability to generate fully mature
hepatocytes from hESCs.
Multiple studies have used DMSO to improve or main-
tain hepatocyte maturity, by for instance maintaining or
increasing expression of nuclear receptors, hepatocyte-spe-
cific TFs, and drug-metabolizing enzymes (Kanebratt and
Andersson, 2008; Nishimura et al., 2003; Su and Waxman,
2004). Therefore, DMSOhas been included in hPSChepato-
cyte differentiation cultures (Basma et al., 2009; Czysz et al.,
2015; Duan et al., 2010; Hay et al., 2008; Kondo et al., 2014;
Szkolnicka et al., 2014; Ulvestad et al., 2013). As DMSO
appears to improve PSC-hepatocyte differentiation, we
repeated the differentiation protocol in the presence of
0.6% DMSO. DMSO generated, in a much more robust
way, definitive endoderm as was reported before (Chetty
et al., 2013). This was associated with a significantly more
homogeneous populationof d28-HLCs.However, stage-spe-
cific transcripts forhepatic endodermmarkers ind8-HNF4A+
cells and hepatocyte markers in d28-AAT+ sorted cells from
cultures with or without DMSO were not significant
different, and transcripts ind28-AAT+ cells fromDMSO-con-
taining cultures remained significantly lower than in PHHs.
H3K27me3 at hepatoblast/hepatocyte marker gene pro-
moters and enhancers were also not reduced in response to
DMSO in d8-HNF4A+ cells and d28-AAT+ cells. Consistent
with the function of DMSO as an HDAC, H3K27ac marks
at the enhancers of marker genes were increased.
Fetal hepatocyte progenitors express EZH2, the histone
lysinemethyltransferase responsible for H3K27 trimethyla-
tion, and EZH2 is required to allow hepatocyte progenitorwith or without DMSO on H3K27me3 Enrichment, Protein, and
time frame (days 6–16) in which 1 mM GSK-343 (referred to as EZH2
ined by both differentiation protocols in the presence or absence of
l.
rs and enhancers OCT4 and hepatic markers in EZH2i-treated (black
cells with or without DMSO.
markers in both differentiation protocols treated with (white) or
y ICC) (G) in EZH2i-treated (bars) compared with non-treated cells
eriments. *p < 0.05 by Student’s t test. See also Figure S5.
expansion in vivo (Koike et al., 2014). Conversely, knock-
down of EZH2 in embryonic murine hepatic progenitors
was reported to promote their differentiation to hepato-
cytes, with an upregulation of several transcriptional regu-
lators of hepatocyte differentiation (Aoki et al., 2010).
Similar findings have also been published for endocrine
pancreas differentiation (Aoki et al., 2010; Xu et al.,
2014). Differentiation of endocrine pancreatic cells to
mature b cells in vitro becomes possible after grafting the
cells in vivo, and this is associated with complete removal
of Polycomb group-mediated repression at stage-specific
genes (Xie et al., 2013a). As EZH2 levels were significantly
higher in d28-AAT+ cells than in PHHs, we tested whether
inhibition of EZH2 would allow further HLC maturation
via reduction of H3K27me3. Even if inhibition of EZH2
reduced H3K27me3 at both regulatory regions of hepato-
cyte genes by 50%, gene expression and protein levels of
mature hepatocyte markers did not change. It is thus
possible that removing only 50% of the H3K27me3 from
HLCs is insufficient to allow full maturation to a PHH
state. Alternatively, it is also possible that the impact of
the repression-associated H3K27me3markingmay be rein-
forced by other repressive histone modifications in hESC
progeny.
In summary, we demonstrate that the in vitro differenti-
ation of hESC-derived cells to hepatocytes is accompanied
by dynamic epigenetic regulation. Although hESC-derived
HLC promoter and enhancer decoration with active epige-
netic marks resembles that in PHHs, repressive H3K27me3
marks at hepatocytemarker gene promoters and enhancers
in HLCs did not reflect histone marking observed in un-
cultured PHHs. Modulation of promoter and enhancer
H3K27me3 marking by inhibition of EZH2 activity did
not yield enhanced hepatocyte maturation. This suggests
that H3K27me3 is not solely responsible for the lack of
maturation of ESC progeny, butmay be reinforced by other
repressive histone modifications. Future studies will be
needed to gain insights into the functional links between
signaling events in the hepatocyte environment that sup-
port the establishment of an epigenetic state more akin to
that of PHHs, thus to optimize differentiation protocols
aimed at generating functional hepatocytes from hPSCs.EXPERIMENTAL PROCEDURES
hESC Differentiation to the Hepatocyte Lineage
The hESC H9 line (WAO9, WiCell) was cultured on inactivated
mouse embryonic fibroblasts (iMEF) as described by Thomson
et al. (1998). Experiments were performed with approval from
theMedical Ethics Committee (UZ Leuven,Gasthuisberg). Hepato-
cyte differentiation was done as described earlier withminor adap-
tations (Roelandt et al., 2013) (Figure 1A). For the DMSO-treated
cell culture condition, cells were supplemented from days 0 to 28to 0.6% DMSO (Sigma-Aldrich). EZH2 inhibition was induced in
the cultures by administration of 1 mM GSK-343 (Sigma-Aldrich,
SML0766) from days 6 to 16 by changing media completely every
2 days. All growth factors were purchased from PeproTech.
FACS
Cells were harvested with 0.05% trypsin-EDTA (d8) or liberase
(d28) (Roche), fixed with 1% ice-cold formaldehyde (Fluka) for
10 min at room temperature, and quenched with 0.125 mM
glycine for 5 min at room temperature. Fixed cells were permeabi-
lized and blocked with 10% goat serum (Dako)/0.1% saponin/PBS
for 45 min at room temperature, followed by incubation with
1 mg/ml/106 cells anti-HNF4A and anti-AAT primary antibodies
(Abs) or isotypes in 1% goat serum/PBS for 1 hr at room tempera-
ture (Table S1). Secondary Abs (Alexa Fluor 488 [1:1000], Alexa
Fluor 555 [1:1000], or Alexa Fluor 647 [1:1500], Invitrogen) were
used for 30 min at room temperature in the dark before sorting
the samples on a FACS AriaIII cell sorter (BD Biosciences). Data
were analyzed with FACS Diva Software (BD Biosciences). Cells
were stored at 80C.
RNA Extraction from FACS-Sorted Cells
Cells were fixed with 1% ice-cold formaldehyde (Fluka) for 10 min
at room temperature, and quenched by adding 0.125 mM glycine
for 5 min supplemented with 1:125 RNasin Plus RNase Inhibitor
(Promega). All the subsequent steps were carried out as described
above under FACS. Cells were washed with PBS containing 1:200
RNasin Plus RNase Inhibitor. RNasin Plus RNase Inhibitor (1:60)
was added to the permeabilization/blocking, primary, and second-
ary solutions. Following secondary Ab staining cells were washed
twice in PBS, and resuspended in PBS with 0.5% goat serum and
1:100 RNasin Plus RNase Inhibitor. Cells were sorted on a FACS
AriaIII cell sorter (BD Biosciences) and were collected in tubes
coated with a small amount of PBS with 0.5% goat serum and
1:100 RNasin Plus RNase Inhibitor. After sorting, cells were recov-
ered by centrifugation at 2,2003 g for 15min at 4C. To reverse the
formaldehyde crosslinking, cell pellets were incubated in 200 mL of
200 mM NaCl, 10 mM Tris-HCl (pH 8), 1 mM EDTA, 1% SDS,
and 1:200 RNasin Plus RNase Inhibitor for 2 hr at 65C (Jeyapalan
and Sedivy, 2013). An equal amount volume of TRIzol reagent
(Ambion) was added. RNA was extracted according to the TRIzol
manufacturer’s instructions.
ICC for Pluripotent and Hepatic Markers
Cells differentiated on glass slides were fixed with 4% paraformal-
dehyde (PFA) for 15 min at room temperature, permeabilized with
0.2%TritonX-100 in PBS (PBS-T), blockedwith 0.2% PBS-T supple-
mented with 5% normal donkey serum (Jackson Laboratory),
and stained overnight at 4C with OCT4 (0.4 mg/mLl), HNF4A
(5 mg/mLl), AFP (4.5 mg/mL), ALB (2.5 mg/mL), AAT (3.95 mg/mL),
or the relevant isotype control Abs in Dako diluents (Dako) (Table
S1). Immune complexes were detected by incubation with a spe-
cies-specific AF555-conjugated immunoglobulin G (4 mg/mL,
Alexa Fluor, Molecular Probes) for 30 min at room temperature.
The nuclei were visualized using Hoechst (Sigma-Aldrich).
Signals were detected with an Axioimager.Z1 microscope (Carl
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percentage of positive cells on days 0, 4, and 8 was manually
counted on five representative 103 images. Differently for AFP,
ALB, and AAT on day 28, which were also detected surrounding
the cells, the percentage of positive signal was based on surface
area measurements using the measurement module software
(Carl Zeiss). For all pictures, the percentage of positive cells was
contoured above the isotype level and three different differentia-
tions were averaged.
ChIP
ChIPwasperformedusing33105or63105 cells per IP, respectively,
for histone modifications (H3K27me3, H3K27ac, and H3K4me3/
me2/me1) and POL2RA. IPs were processed as described previously
(Pistoni et al., 2010). Dynabeads (Life Technologies) were added
and DNA purified using a QIAquick PCR purification kit (Qiagen).
Purified DNA was analyzed by qPCR. Identification of promoter
and enhancer regionswas based on literature research and the Ency-
clopedia of DNA elements (ENCODE) database, available online. Se-
quencesof theprimers andChIP-gradeAbsused forChIPare listed in
Tables S2 and S3. The ChIP-qPCR data were presented as percent
input/total H3: for the histone modifications we calculated by
2((CT Histone modification  CT 10% input))/2((CT total H3  CT 10% input))
and for POL2RAwe calculated by 2((CT POL2RA  CT 10% input)).
Statistical Analysis
Comparisons between two data groups (with nR 3 independent
experiments) were analyzed using an unpaired two-tailed Stu-
dent’s t test (GraphPad Prism 5) (De winter, 2013). p Values of
less than 0.05 were considered significant and are indicated in
the graphs as *p < 0.05, **p < 0.01, or ***p < 0.001. All data repre-
sent the mean ± SEM (nR 3) or mean ± SD (n = 2). To investigate
the relationship between cell population (d8-HNF4A+ versus
d8-HNF4A cells and d28-AAT+ cells versus PHHs) and histone
enrichment via gene expression levels, a mediation analysis was
performed (Krull and MacKinnon, 1999). This involved a regres-
sion of gene expression level on cell population, and regression
models of each histone modification on gene expression levels.
In all models, gene was used as a repeated measure to obtain rela-
tionships averaged over all genes, and gene and histone levels
were log transformed due to heavy skewness. The indirect effect
of cell population on gene expression for each histone modifica-
tion was then obtained by combining the models using the Sobel
method (Krull and MacKinnon, 1999).
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